Avidity Biosciences (RNA) Non-Current Deffered Revenue (2019 - 2025)
Historic Non-Current Deffered Revenue for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $32.1 million.
- Avidity Biosciences' Non-Current Deffered Revenue fell 2412.39% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year decrease of 2412.39%. This contributed to the annual value of $38.0 million for FY2024, which is 718.13% down from last year.
- Latest data reveals that Avidity Biosciences reported Non-Current Deffered Revenue of $32.1 million as of Q3 2025, which was down 2412.39% from $40.0 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Non-Current Deffered Revenue registered a high of $43.4 million during Q1 2025, and its lowest value of $1.2 million during Q4 2022.
- Its 5-year average for Non-Current Deffered Revenue is $22.5 million, with a median of $21.1 million in 2021.
- In the last 5 years, Avidity Biosciences' Non-Current Deffered Revenue crashed by 8109.31% in 2022 and then surged by 321157.89% in 2023.
- Avidity Biosciences' Non-Current Deffered Revenue (Quarter) stood at $6.5 million in 2021, then plummeted by 81.09% to $1.2 million in 2022, then surged by 3211.58% to $40.9 million in 2023, then fell by 7.18% to $38.0 million in 2024, then dropped by 15.53% to $32.1 million in 2025.
- Its Non-Current Deffered Revenue was $32.1 million in Q3 2025, compared to $40.0 million in Q2 2025 and $43.4 million in Q1 2025.